Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, outlines the rationale behind using chimeric antigen receptor T-cells (CAR-Ts) for the treatment of hepatitis B and hepatitis B virus-associated liver cancer. Since viruses deposit proteins on the surface of infected cells, it is possible to design a CAR construct targeting this protein. In addition, upon infection, the hepatitis B virus persists in cells without immediately killing them, which makes it an interesting virus to target with a CAR-T. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.